Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts

Hepatology Communications

Volumn 2, Issue 7, 2018, Pages 807-820

  Mayo, Rebeca ^a   Crespo, Javier ^b   Martínez Arranz, Ibon ^a   Banales, Jesus M ^c   Arias, Mayte ^b   Mincholé, Itziar ^a   Aller de la Fuente, Rocío ^d   Jimenez Agüero, Raúl ^c   Alonso, Cristina ^a   de Luis, Daniel A ^d   Vitek, Libor ^e   Stritesky, Jan ^e   Caballería, Joan ^f   Romero Gómez, Manuel ^g   Martín Duce, Antonio ^h   Mugüerza Huguet, Jose Maria ^h   Busteros Moraza, José Ignacio ^h   Idowu, Michael O ⁱ   Castro, Azucena ^a   Martínez Chantar, M Luz ^j   Ortiz, Pablo ^a   Bruha, Radan ^e   Lu, Shelly C ^k   Bedossa, Pierre ^l   Noureddin, Mazen ^k   Sanyal, Arun J ⁱ   Mato, José M ^j   more..

^a Proteomics Platform   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^e CHARLES UNIVERSITY   (Czech Republic)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

ⁱ VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^j CIC BIOGUNE   (Spain)

^k CEDARS SINAI MEDICAL CENTER   (United States)

^l Paris Nord Val de Seine University Hospitals   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLUCOSE; LIPID; TRIACYLGLYCEROL;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; FALSE POSITIVE RESULT; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER BIOPSY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION STUDY;

EID: 85057856409     PISSN: None     EISSN: 2471254X     Source Type: Journal    
DOI: 10.1002/hep4.1188     Document Type: Article

References (49)

1. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009;13:631-647
2. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-1832
3. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-161
4. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009;41:615-625
5. Mishra A, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol 2012;2:135-144
6. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009;250:691-697
7. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al.; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906
8. Idilman IS, Aniktar H, Idilman R, Kabacam G, Savas B, Elhan A, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 2013;267:767-775
9. Nasr P, Forsgren MF, Ignatova S, Dahlström N, Cedersund G, Leinhard OD, et al. Using a 3% proton density fat fraction as a cut-off value increases sensitivity of detection of hepatic steatosis, based on results from histopathology analysis. Gastroenterology 2017;153:53-55.e7
10. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013;58:1930-1940
11. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol 2016;65:1006-1016
12. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 2013;37:544-555
13. Cui J, Heba E, Hernandez C, Haufe W, Hooker J, Andre MP, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. Hepatology 2016;63:453-461
14. Hannah WN, Torres DM, Harrison SA. Nonalcoholic steatohepatitis and endpoints in clinical trials. Gastroenterol Hepatol (N Y) 2016;12:756-763
15. Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015;64:800-812
16. Afonso MB, Rodrigues PM, Simao AL, Castro RE. Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma. J Clin Med 2016;5.pii.E30
17. Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012;56:1363-1370
18. Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis. PLoS One 2015;10:e0131664
19. Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res 2012;11:2521-2532
20. Alonso C, Fernández-Ramos D, Varela-Rey M, Martínez-Arranz I, Navasa N, Van Liempd SM, et al. Metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology 2017;152:1449-1461.e7
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321
22. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, et al.; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-820
23. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-1402
24. Martínez-Arranz I, Mayo R, Pérez-Cormenzana M, Mincholé I, Salazar L, Alonso C, et al. Enhancing metabolomics research through data mining. J Proteomics 2015;127:275-288
25. rd ed. Boca Raton, FL: CRC Press; 2008
26. R Development CoreTeam. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Available at: https://www.r-project.org; 2017
27. Ogawa Y, Imajo K, Yoneda M, Nakajima A. Pathophysiology of NAsh/NAFLD associated with high levels of serum triglycerides. [in Japanese] Nihon Rinsho 2013;71:1623-1629
28. Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr 2015;4:101-108
29. Williams KH, Shackel NA, Gorrell MD, Mclennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease: Endocr Rev 2013;34:84-129
30. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 2017;152:598-607.e2
31. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al.; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023
32. Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, et al. Poor inter-test reliability between CK18 kits as a biomarker of NASH. Dig Dis Sci 2016;61:905-912
33. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-36
34. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The enhanced liver fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013;59:236-242
35. Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, et al.; FLIP Consortium and the FibroFrance Group. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther 2016;44:877-889
36. Trivedi DK, Hollywood KA, Goodacre R. Metabolomics for the masses: the future of metabolomics in a personalized world. New Horiz Transl Med 2017;3:294-305
37. Pietiläinen KH, Sysi-Aho M, Rissanen A, Seppänen-Laakso T, Yki-Järvinen H, Kaprio J, et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study. PLoS One 2007;2:e218
38. Oberbach A, Blüher M, Wirth H, Till H, Kovacs P, Kullnick Y, et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J Proteome Res 2011;10:4769-4788
39. Kim JY, Park JY, Kim OY, Ham BM, Kim H-J, Kwon DY, et al. Metabolic profiling of plasma in overweight/obese and lean men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC-Q-TOF MS). J Proteome Res 2010;9:4368-4375
40. Ritchie SA, Heath D, Yamazaki Y, Grimmalt B, Kavianpour A, Krenitsky K, et al. Reduction of novel circulating long-chain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol 2010;10:140
41. Alonso C, Mato JM. Nonalcoholic fatty liver disease. In: Wilson ID, Theodoridis G, Nicholls, A, eds. Global Metabolic Profiling: Clinical Applications. London, United Kingdom: Future Science Ltd; 2014:110-122
42. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013;48:434-441
43. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-1664
44. Wu X, Tong Y, Shankar K, Baumgardner JN, Kang J, Badeaux J, et al. Lipid fatty acid profile analyses in liver and serum in rats with nonalcoholic steatohepatitis using improved gas chromatography-mass spectrometry methodology. J Agric Food Chem 2011;59:747-754
45. Maxim LD, Niebo R, Utell MJ. Screening tests: A review with examples. Inhal Toxicol 2014;26:811-828
46. Noureddin M, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, Mccullough A, et al.; NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013;58:1644-1654
47. Gan L, Chitturi S, Farrell GC. Mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly. Curr Gerontol Geriatr Res 2011;2011:831536
48. Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, et al. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology 2009;50:772-780
49. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007;128:837-847